Fonsecaea pedrosoi infection induces differential modulation of costimulatory molecules and cytokines in monocytes from patients with severe and mild forms of chromoblastomycosis

Journal of Leukocyte Biology

Volumn 84, Issue 3, 2008, Pages 864-870

  Sousa, Maria Glória Teixeira ^a   Silva Azevedo, Conceição De Maria Pedrozo ^b   Nascimento, Rosana Cicera ^a   Ghosn, Eliver Eid Bou ^a   Santiago, Karla Leticia ^a   Noal, Vanessa ^a   Bomfim, Gisele Facholi ^a   Marques, Sirlei Garcia ^b   Gonçalves, Azizedite Guedes ^b   Santos, Daniel Wagner De Castro Lima ^b   Almeida, Sandro Rogerio ^a,b  

^a FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

IL 10; IL 12; Immune regulation; Th1 Th2

Indexed keywords

CYTOKINE; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; RECOMBINANT CYTOKINE; RECOMBINANT IINTERLEUKIN 12; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL PROLIFERATION; CELL STIMULATION; CHROMOMYCOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FONSECAEA PEDROSOI; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD80; ASCOMYCOTA; CELL COMMUNICATION; CELL PROLIFERATION; CHROMOBLASTOMYCOSIS; CYTOKINES; FEMALE; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MONOCYTES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

FONSECAEA PEDROSOI;

EID: 50849118827     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0308211     Document Type: Article

References (23)

1. Salgado, C. G., da Silva, J. P., Diniz, J. A., da Silva, M. B., da Costa, P. F., Teixeira, C., Salgado, U. I. (2004) Isolation of Fonsecaea pedrosoi from thorns of Mimosa pudica, a probable natural source of chromoblastomycosis. Rev. Inst. Med. Trop. Sao Paulo 46, 33-36.
2. Burks, J. B., Wakabongo, M., McGinnis, M. R. (1995) Chromoblastomycosis. A fungal infection primarily observed in the lower extremity. J. Am. Podiatr. Med. Assoc. 85, 260-264.
3. Marques, S. G., Pedrozo Silva, C. M., Resende, M. A., Andreata, L. S., Costa, J. M. (2004) Chromoblastomycosis caused by Rhinocladiella aquaspersa. Med. Mycol. 42, 261-265.
4. Esterre, P., Andriantsimahavandy, A., Ramarcel, E. R., Pecarrere, J. L. (1996) Forty years of chromoblastomycosis in Madagascar: a review. Am. J. Trop. Med. Hyg. 55, 45-47.
5. Minotto, R., Bernardi, C. D., Mallmann, L. F., Edelweiss, M. I., Scroferneker, M. L. (2001) Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. J. Am. Acad. Dermatol. 44, 585-592.
6. Bonifaz, A., Carrasco-Gerard, E., Saul, A. (2001) Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses 44, 1-7.
7. d'Avila, S. C., Pagliari, C., Duarte, M. I. (2003) The cell-mediated immune reaction in the cutaneous lesion of chromoblastomycosis and their correlation with different clinical forms of the disease. Mycopathologia 156, 51-60.
8. Mazo Favero Gimenes, V., Da Gloria de Souza, M., Ferreira, K. S., Marques, S. G., Goncalves, A. G., Vagner de Castro Lima Santos, D., Pedroso e Silva Cde, M., Almeida, S. R. (2005) Cytokines and lymphocyte proliferation in patients with different clinical forms of chromoblastomycosis. Microbes Infect. 7, 708-713.
9. Fuchs, J., Pecher, S. (1992) Partial suppression of cell mediated immunity in chromoblastomycosis. Mycopathologia 119, 73-76.
10. Teixeira de Sousa Mda, G., Ghosn, E. E., Almeida, S. R. (2006) Absence of CD4+ T cells impairs host defense of mice infected with Fonsecaea pedrosoi. Scand. J. Immunol. 64, 595-600.
11. Carrion, A. L. (1950) Chromoblastomycosis. Ann. N. Y. Acad. Sci. 50, 1255-1282.
12. Queiroz-Telles, F., Purim, K. S., Fillus, J. N., Bordignon, G. F., Lameira, R. P., Van Cutsem, J., Cauwenbergh, G. (1992) Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int. J. Dermatol. 31, 805-812.
13. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
14. Ropert, C., Gazzinelli, R. T. (2000) Signaling of immune system cells by glycosylphosphatidylinositol (GPI) anchor and related structures derived from parasitic protozoa. Curr. Opin. Microbiol. 3, 395-403.
15. Marr, K. A., Patterson, T., Denning, D. (2002) Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect. Dis. Clin. North Am. 16, 875-894.
16. Fidel Jr., P. L., Sobel, J. D. (1994) The role of cell-mediated immunity in candidiasis. Trends Microbiol. 2, 202-206.
17. Puccetti, P., Romani, L., Bistoni, F. (1995) A TH1-TH2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol. 3, 237-240.
18. De Becker, G., Moulin, V., Tielemans, F., De Mattia, F., Urbain, J., Leo, O., Moser, M. (1998) Regulation of T helper cell differentiation in vivo by soluble and membrane proteins provided by antigen-presenting cells. Eur. J. Immunol. 28, 3161-3171.
19. Kidd, P. (2003) Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 8, 223-246.
20. Bacellar, O., D'Oliveira Jr., A., Jeronimo, S., Carvalho, E. M. (2000) IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 12, 1228-1231.
21. Romano, C. C., Mendes-Giannini, M. J., Duarte, A. J., Benard, G. (2002) IL-12 and neutralization of endogenous IL-10 revert the in vitro antigen-specific cellular immunosuppression of paracoccidioidomycosis patients. Cytokine 18, 149-157.
22. Li, J., Sutterwala, S., Farrell, J. P. (1997) Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and γ interferon depends on continued interleukin-12 production. Infect. Immun. 65, 3225-3230.
23. Imami, N., Hardy, G., Pires, A., Burton, C., Pido-Lopez, J., Mela, C., Gotch, F. (2002) Immune reconstitution in HIV-1-infected patients. Curr. Opin. Investig. Drugs 3, 1138-1145.